Barclays PLC Natera, Inc. Transaction History

Barclays PLC

$357 Billion
Q4 2024

A detailed history of Barclays PLC transactions in Natera, Inc. stock. As of the latest transaction made, Barclays PLC holds 111,411 shares of NTRA stock, worth $16.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

111,411

Previous 140,115 20.49%

Holding current value

$16.5 Million

Previous $17.8 Million 0.85%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	SELL	$117.67 - $174.0 $3.38 Million - $4.99 Million	-28,704 Reduced 20.49%	111,411 $17.6 Million
Q3 2024 Nov 15, 2024	BUY	$97.75 - $129.67 $7.16 Million - $9.5 Million	73,250 Added 109.55%	140,115 $17.8 Million
Q2 2024 Aug 14, 2024	BUY	$85.28 - $112.6 $2.29 Million - $3.02 Million	26,852 Added 67.11%	66,865 $7.24 Million
Q1 2024 May 15, 2024	SELL	$59.21 - $92.9 $2.99 Million - $4.69 Million	-50,474 Reduced 55.78%	40,013 $3.66 Million
Q4 2023 Feb 15, 2024	SELL	$37.55 - $62.64 $254,288 - $424,198	-6,772 Reduced 6.96%	90,487 $5.67 Million
Q3 2023 Nov 07, 2023	SELL	$43.4 - $62.52 $732,852 - $1.06 Million	-16,886 Reduced 14.79%	97,259 $4.3 Million
Q2 2023 Aug 03, 2023	SELL	$47.08 - $55.16 $196,653 - $230,403	-4,177 Reduced 3.53%	114,145 $5.56 Million
Q1 2023 May 04, 2023	SELL	$36.57 - $58.29 $12 Million - $19.2 Million	-329,285 Reduced 73.57%	118,322 $6.57 Million
Q4 2022 Feb 13, 2023	BUY	$34.17 - $47.91 $11.7 Million - $16.4 Million	341,396 Added 321.43%	447,607 $18 Million
Q3 2022 Nov 03, 2022	BUY	$36.93 - $56.68 $2.9 Million - $4.46 Million	78,630 Added 285.09%	106,211 $4.66 Million
Q2 2022 Aug 12, 2022	BUY	$28.13 - $44.54 $138,624 - $219,493	4,928 Added 21.75%	27,581 $978,000
Q1 2022 May 16, 2022	BUY	$30.32 - $91.33 $125,585 - $378,288	4,142 Added 22.38%	22,653 $921,000
Q4 2021 Feb 14, 2022	SELL	$86.26 - $119.0 $954,811 - $1.32 Million	-11,069 Reduced 37.42%	18,511 $1.73 Million
Q3 2021 Nov 09, 2021	SELL	$100.17 - $126.36 $2.07 Million - $2.61 Million	-20,693 Reduced 41.16%	29,580 $3.3 Million
Q2 2021 Aug 13, 2021	SELL	$86.05 - $119.72 $2.81 Million - $3.92 Million	-32,705 Reduced 39.41%	50,273 $5.71 Million
Q1 2021 May 13, 2021	BUY	$91.47 - $124.36 $4.3 Million - $5.84 Million	46,991 Added 130.58%	82,978 $8.43 Million
Q4 2020 Feb 11, 2021	SELL	$66.66 - $111.74 $5.38 Million - $9.01 Million	-80,652 Reduced 69.15%	35,987 $3.58 Million
Q3 2020 Nov 12, 2020	BUY	$45.89 - $72.67 $3.51 Million - $5.56 Million	76,507 Added 190.64%	116,639 $8.43 Million
Q2 2020 Aug 12, 2020	BUY	$26.36 - $49.86 $400,408 - $757,373	15,190 Added 60.9%	40,132 $2 Million
Q1 2020 May 13, 2020	SELL	$17.27 - $40.17 $815,575 - $1.9 Million	-47,225 Reduced 65.44%	24,942 $745,000
Q4 2019 Feb 10, 2020	BUY	$32.1 - $40.4 $1.15 Million - $1.45 Million	35,979 Added 99.42%	72,167 $2.43 Million
Q3 2019 Nov 14, 2019	BUY	$25.38 - $34.89 $2,817 - $3,872	111 Added 0.31%	36,188 $1.19 Million
Q2 2019 Aug 14, 2019	BUY	$17.75 - $27.58 $287,798 - $447,182	16,214 Added 81.63%	36,077 $995,000
Q1 2019 May 15, 2019	SELL	$11.34 - $20.62 $700,551 - $1.27 Million	-61,777 Reduced 75.67%	19,863 $410,000
Q4 2018 Feb 14, 2019	BUY	$12.32 - $24.38 $780,767 - $1.55 Million	63,374 Added 346.95%	81,640 $1.14 Million
Q3 2018 Nov 14, 2018	SELL	$18.82 - $28.96 $19,986 - $30,755	-1,062 Reduced 5.49%	18,266 $437,000
Q2 2018 Aug 14, 2018	BUY	$8.79 - $19.98 $20,691 - $47,032	2,354 Added 13.87%	19,328 $363,000
Q1 2018 May 15, 2018	BUY	$9.0 - $11.95 $20,781 - $27,592	2,309 Added 15.74%	16,974 $157,000
Q4 2017 Feb 14, 2018	SELL	$8.99 - $14.31 $52,483 - $83,541	-5,838 Reduced 28.47%	14,665 $132,000
Q3 2017 Nov 14, 2017	BUY	$8.02 - $13.33 $164,434 - $273,304	20,503	20,503 $265,000

Others Institutions Holding NTRA

# of Institutions

635

Shares Held

123M

Call Options Held

821K

Put Options Held

1.01M

View Full List

About Natera, Inc.

Ticker NTRA
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 96,957,400
Market Cap $14.3B
Description
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify sing...

More about NTRA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account